1. Home
  2. VWAV vs ACET Comparison

VWAV vs ACET Comparison

Compare VWAV & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VisionWave Holdings Inc.

VWAV

VisionWave Holdings Inc.

N/A

Current Price

$2.58

Market Cap

36.4M

Sector

Technology

ML Signal

N/A

ACET

Adicet Bio Inc.

N/A

Current Price

$3.41

Market Cap

33.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VWAV
ACET
Founded
2024
1947
Country
United States
United States
Employees
N/A
102
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
36.4M
33.5M
IPO Year
2025
2017

Fundamental Metrics

Financial Performance
Metric
VWAV
ACET
Price
$2.58
$3.41
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
★ $34.83
AVG Volume (30 Days)
★ 197.1K
187.5K
Earning Date
08-19-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.26
$0.46
52 Week High
$79,000.00
$9.97

Technical Indicators

Market Signals
Indicator
VWAV
ACET
Relative Strength Index (RSI) 19.39 18.83
Support Level $0.26 N/A
Resistance Level $5.79 $9.59
Average True Range (ATR) 0.56 0.34
MACD 130.16 -0.02
Stochastic Oscillator 17.14 3.39

Price Performance

Historical Comparison
VWAV
ACET

About VWAV VisionWave Holdings Inc.

VisionWave Holdings Inc is a technology company focused on the development and commercialization of artificial intelligence (AI) and autonomous solutions across air, ground and sea environments. Through its subsidiary, the Company designs and deploys technologies including radars, radio frequency (RF) sensing, unmanned aerial and ground systems, remote weapon stations and active protection systems for defense, military, homeland security and industrial applications. Its proprietary AI engine supports autonomous decision-making and product lines at various stages of development and commercialization. Revenue is generated through product sales, technology licensing, strategic alliances and joint ventures, with products including C-UAS, multi-purpose autonomous UAS and Vision-AI technology.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).

Share on Social Networks: